Beta Bionics, using its iLet system, started the first at home trial using both insulin and glucagon to control blood glucose. Here’s the opening paragraph of the press release.
Boston, MA and Copenhagen, Denmark, May 22, 2019 – Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL) announced today the first patients dosed in a clinical trial investigating the home-use of dasiglucagon in the iLetTM Bionic Pancreas System. The iLet, developed by Beta Bionics, is the world’sfirst autonomous bionic pancreas device — a bihormonal system leveraging lifelong machine learning and artificial intelligence to deliver insulin and glucagon analogs for the autonomous treatment of type 1 diabetes. In addition to dosing insulin, the iLet doses dasiglucagon — a glucagon analog developed by Zealand Pharma with a unique stability profile in a ready-to-use aqueous solution.
It’s promising that a shelf-stable glucagon is finally in the mix. This might be the “killer-app” of the automated insulin dosing category. We shall see.